These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21899208)

  • 1. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
    Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
    Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative effect of several intravenous iron complexes in the rat.
    Bailie GR; Schuler C; Leggett RE; Li H; Li HD; Patadia H; Levin R
    Biometals; 2013 Jun; 26(3):473-8. PubMed ID: 23681275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.
    Toblli JE; Cao G; Rico L; Angerosa M
    Drug Des Devel Ther; 2017; 11():3401-3412. PubMed ID: 29238166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*.
    Heming N; Lettéron P; Driss F; Millot S; El Benna J; Tourret J; Denamur E; Montravers P; Beaumont C; Lasocki S
    Crit Care Med; 2012 Jul; 40(7):2141-8. PubMed ID: 22564959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
    Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
    J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
    Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
    J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferrous iron content of intravenous iron formulations.
    Gupta A; Pratt RD; Crumbliss AL
    Biometals; 2016 Jun; 29(3):411-5. PubMed ID: 26956439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
    Connor JR; Zhang X; Nixon AM; Webb B; Perno JR
    PLoS One; 2015; 10(5):e0125272. PubMed ID: 25973894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
    Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.
    Lim CS; Vaziri ND
    Kidney Int; 2004 May; 65(5):1802-9. PubMed ID: 15086920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
    Hempel JC; Poppelaars F; Gaya da Costa M; Franssen CF; de Vlaam TP; Daha MR; Berger SP; Seelen MA; Gaillard CA
    Am J Nephrol; 2017; 45(1):49-59. PubMed ID: 27889746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.